Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

42 Drugs in Development

42 Drugs in Development

DIGITAL CONTENT

29 NEWS #PharmaBuzz

media
29 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

42DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 2-cl-ib-meca, 163042-96-4, Namodenoson, Cl-ib-meca, Cf-102, Cf102

Molecular Formula

C₁₈H₁₈ClIN₆O₄

Molecular Weight

544.7 g/mol

InChI Key

IPSYPUKKXMNCNQ-PFHKOEEOSA-N

FDA UNII

Z07JR07J6C

Namodenoson is an orally bioavailable, synthetic, highly selective adenosine A3 receptor (A3AR) agonist with potential antineoplastic activity. Namodenoson selectively binds to and activates the cell surface-expressed A3AR, deregulating Wnt and NF-kB signal transduction pathways downstream, which may result in apoptosis of A3AR-expressing tumor cells. A3AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of various solid tumor cell types, including hepatocellular carcinoma (HCC) cells, and plays an important role in cellular proliferation.

1 2D Structure

Namodenoson

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2S,3S,4R,5R)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide

2.1.2 InChI

InChI=1S/C18H18ClIN6O4/c1-21-16(29)13-11(27)12(28)17(30-13)26-7-23-10-14(24-18(19)25-15(10)26)22-6-8-3-2-4-9(20)5-8/h2-5,7,11-13,17,27-28H,6H2,1H3,(H,21,29)(H,22,24,25)/t11-,12+,13-,17+/m0/s1

2.1.3 InChI Key

IPSYPUKKXMNCNQ-PFHKOEEOSA-N

2.1.4 Canonical SMILES

CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O

2.1.5 Isomeric SMILES

CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O

2.2 Other Identifiers

2.2.1 UNII

Z07JR07J6C

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-chloro-n(6)-(3-iodobenzyl)-9-(5-(methylcarbamoyl)-beta-d-ribofuranosyl)adenine

2. 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide

3. 2-chloro-n6-(3-iodobenzyl)adenosine-5'-n-methylcarboxamide

4. 2-cl-ib-meca

5. C-ibza-mu

6. Cf102 Compound

2.3.2 Depositor-Supplied Synonyms

1. 2-cl-ib-meca

2. 163042-96-4

3. Namodenoson

4. Cl-ib-meca

5. Cf-102

6. Cf102

7. C-ibza-mu

8. (2s,3s,4r,5r)-5-(2-chloro-6-((3-iodobenzyl)amino)-9h-purin-9-yl)-3,4-dihydroxy-n-methyltetrahydrofuran-2-carboxamide

9. Ci-ib-meca

10. 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide

11. Namodenoson [usan]

12. 2cl-ib-meca

13. (2s,3s,4r,5r)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide

14. Chembl431733

15. Z07jr07j6c

16. 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-1-deoxy-n-methyl-beta-d-ribofuranuronamide

17. Unii-z07jr07j6c

18. 1-(2-chloro-6-(((3-iodophenyl)methyl)amino)-9h-purin-9-yl)-1-deoxy-n-methyl-beta-d-ribofuranuronamide

19. Beta-d-ribofuranuronamide, 1-(2-chloro-6-(((3-iodophenyl)methyl)amino)-9h-purin-9-yl)-1-deoxy-n-methyl-

20. Beta-d-ribofuranuronamide, 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-1-deoxy-n-methyl-

21. Cf 102

22. 2-chloro-n6-(3-iodobenzyl)adenosine-5'-n-methylcarboxamide

23. Namodenoson [inn]

24. Namodenoson (cf-102)

25. Namodenoson (usan/inn)

26. C1-ib-meca

27. 2-chloro-n(6)-(3-iodobenzyl)-9-(5-(methylcarbamoyl)-beta-d-ribofuranosyl)adenine

28. Gtpl457

29. Namodenoson [who-dd]

30. Mls002153535

31. Schembl1170028

32. Bdbm21221

33. 2-chloro-n6-(3-iodobenzyl)adenosine-5'-n-methyluronamide

34. Cf-102;2-cl-ib-meca

35. Dtxsid80167504

36. Hms2235l10

37. Hms3412i05

38. Hms3676i05

39. Cf-102(2-cl-ib-meca)

40. Ex-a2882

41. Zinc3995845

42. Mfcd01861178

43. Akos022181265

44. Am84557

45. Cs-5932

46. Db12885

47. Ncgc00025001-02

48. Ac-27390

49. Ds-16397

50. Hy-12365

51. Smr001230862

52. Chloro-ib-meca, Solid, >=98% (hplc)

53. B6597

54. C3601

55. S0498

56. D11128

57. P10208

58. A848899

59. J-009992

60. Q27076097

61. 2-chloro-n6-(3-iodobenzyl)adenosine-5-n-methylcarboxamide

62. (2s,3s,4r,5r)-5-(2-chloro-6-(3-iodobenzylamino)-9h-purin-9-yl)-3,4-dihydroxy-n-methyltetrahydrofuran-2-carboxamide

63. (2s,3s,4r,5r)-5-(2-chloro-6-{[(3-iodophenyl)methyl]amino}-9h-purin-9-yl)-3,4-dihydroxy-n-methyloxolane-2-carboxamide

64. (2s,3s,4r,5r)-5-(6-(3-iodobenzylamino)-2-chloro-9h-purin-9-yl)-3,4-dihydroxy-n-methyl-tetrahydrofuran-2-carboxamide

65. .beta.-d-ribofuranuronamide, 1-(2-chloro-6-(((3-iodophenyl)methyl)amino)-9h-purin-9-yl)-1-deoxy-n-methyl-

66. 1-(2-chloro-6-(((3-iodophenyl)methyl)amino)-9h-purin-9-yl)-1-deoxy-n-methyl-.beta.-d-ribofuranuronamide

67. 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-1-deoxy-n-methyl-?-d-ribofuranuronamide

68. 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-1-deoxy-n-methyl-beta-d-ribofuranuronamide;2-chloro-n6-(3-iodobenzyl)adenosine-5'-n-methyluronamide;2-cl-ib-meca;2-cl-ib-meca

2.4 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₁₈H₁₈ClIN₆O₄
Molecular Weight	544.7 g/mol
XLogP3	1.9
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	5
Exact Mass	544.01228 g/mol
Monoisotopic Mass	544.01228 g/mol
Topological Polar Surface Area	134 Å²
Heavy Atom Count	30
Formal Charge	0
Complexity	623
Isotope Atom Count	0
Defined Atom Stereocenter Count	4
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Purinergic P1 Receptor Agonists

Compounds that bind to and stimulate PURINERGIC P1 RECEPTORS. (See all compounds classified as Purinergic P1 Receptor Agonists.)

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Find Namodenoson manufacturers, exporters & distributors on PharmaCompass

Namodenoson

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DEVELOPMENTS

42 Drugs in Development

DIGITAL CONTENT

29 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

42DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?